CYP19 (Aromatase) haplotypes and endometrial cancer risk

International Journal of Cancer

Volumn 116, Issue 2, 2005, Pages 267-274

  Paynter, Randi A ^a,d   Hankinson, Susan E ^a,b   Colditz, Graham A ^a,b,c   Kraft, Peter ^a   Hunter, David J ^a,b,c   De Vivo, Immaculata ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD CENTER FOR CANCER PREVENTION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aromatase; Endometrial cancer; Haplotype; Hormonal carcinogenesis; Polymorphism

Indexed keywords

ANDROSTENEDIONE; AROMATASE; ESTRADIOL; ESTROGEN; ESTRONE; STEROID HORMONE; TESTOSTERONE;

ADULT; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HORMONE BLOOD LEVEL; HUMAN; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANDROGENS; AROMATASE; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RISK FACTORS;

EID: 22044441714     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21041     Document Type: Article

References (44)

1. McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD Jr, Kurland LT. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977;127:572-80.
2. Key TJ, Pike MC. The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
3. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
4. Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E. Family history and the risk of endometrial cancer. Int J Cancer 1994;59:460-2.
5. Sandles LG, Shulman LP, Elias S, Photopulos GJ, Smiley LM, Posten WM, Simpson JL. Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. Gynecol Oncol 1992;47:167-71.
6. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:411-7.
7. Bulun SE, Zeitoun K, Sasano H, Simpson ER. Aromatase in aging women. Semin Reprod Endocrinol 1999;17:349-58.
8. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson CR. Tissue-specific promoters regulate aromatase cytochrome P450 expression. J Steroid Biochem Mol Biol 1993;44:321-30.
9. Sebastian S, Bulun SE. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J Clin Endocrinol Metab 2001;86:4600-2.
10. Berstein LM, Imyanitov EN, Suspitsin EN, Grigoriev MY, Sokolov EP, Togo A, Hanson KP, Poroshina TE, Vasiljev DA, Kovalevskij AY, Gamajunova VB. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 2001;127:135-8.
11. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130-7.
12. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092-6.
13. Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T, Honjo H. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 2002;17:897-902.
14. Arvanitis DA, Koumantakis GE, Goumenou AG, Matalliotakis IM, Koumantakis EE, Spandidos DA. CYP1A1, CYP19, and GSTM1 polymorphisms increase the risk of endometriosis. Fertil Steril 2003;79(Suppl 1):702-9.
15. Masi L, Becherini L, Gennari L, Amedei A, Colli E, Falchetti A, Farci M, Silvestri S, Gonnelli S, Brandi ML. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 2001;86:2263-9.
16. Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol 1994;13:331-7.
17. Watanabe J, Harada N, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics 1997;7:419-24.
18. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk. Br J Cancer 1999;79:456-63.
19. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-8.
20. Nativelle-Serpentini C, Lambard S, Seralini GE, Sourdaine P. Aromatase and breast cancer: W39R, an inactive protein. Eur J Endocrinol 2002;146:583-9.
21. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998;8:43-8.
22. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-73.
23. Healey CS, Dunning AM, Durocher F, Teare D, Pharoah PD, Luben RN, Easton DF, Ponder BA. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-93.
24. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10.
25. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-9.
26. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
27. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19:1329-33.
28. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:215-6.
29. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J, Henderson BE. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
30. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-54.
31. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
32. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health 1993;14:43-68.
33. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-7.
34. Stram DO, Haiman CA, Hirschhom JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
35. Sebastiani P, Lazarus R, Weiss ST, Kunkel LM, Kohane IS, Ramoni MF. Minimal haplotype tagging. Proc Natl Acad Sci USA 2003;100:9900-5.
36. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53:79-91.
37. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Thomas DC. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-90.
38. Levin ML. The occurrence of lung cancer in man. Acta Union Int Contra Cancrum 1953;9:531-41.
39. Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002;102:172-8.
40. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
41. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 2000;67:947-59.
42. Tishkoff SA, Pakstis AJ, Ruano G, Kidd KK. The accuracy of statistical methods for estimation of haplotype frequencies: an example from the CD4 locus. Am J Hum Genet 2000;67:518-22.
43. Shozu M, Zhao Y, Bulun SE, Simpson ER. Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, 1.6. Endocrinology 1998;139:1610-7.
44. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878-84.